Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients
    Meeting Abstract

    Italiano, A.; Hong, D. S.; Briggs, A.; Garcia-Foncillas, J.; Lassen, U. N.; Vassal, G.; Kummar, S.; van Tilburg, C. M.; Keating, K.; Reeves, J. A.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Meeting Abstract

    Drilon, A.; Paz-Ares, L.; Doebele, R. C.; Farago, A. F.; Liu, S. V.; Chawla, S. P.; Tosi, D.; Blakely, C. M.; Krauss, J. C.; Bazhenova, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Tepotinib exposure-response analyses of safety and efficacy in patients with solid tumours
    Meeting Abstract

    Paik, P. K.; Xiong, W.; Hietala, S. F.; Nyberg, J.; Papasouliotis, O.; Anziano, R.; Berghoff, K.; Johne, A.; Girard, P.; Strotmann, R.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Activity, safety and circulating tumour DNA (ctDNA) dynamics of paradox breaker BRAF inhibitor PLX8394 in patients with advanced cancer
    Meeting Abstract

    Gouda, M. A.; Sherman, E. J.; Gilcrease, G. W.; Vaishampayan, U. N.; Parikh, A.; Feun, L.; Kummar, S.; Huang, H.; Zhang, C.; Severson, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study
    Meeting Abstract

    Conley, A. P.; Demetri, G. D.; Doebele, R. C.; Drilon, A.; Paz-Ares, L.; Cassier, P.; Siena, S.; Ahn, M. J.; Buchschacher, G. L. Jr; Seto, T.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy
    Meeting Abstract

    Liu, S. V.; De Braud, F.; Drilon, A.; Doebele, R. C.; Patel, M. R.; Cho, B. C.; Ahn, M. J.; Chiu, C. H.; Farago, A. F.; Goto, K.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer
    Meeting Abstract

    Strickler, J.; Ng, K.; Cercek, A.; Fountzilas, C.; Sanchez, F.; Hubbard, J.; Wu, C.; Stecher, M.; Walker, L. N.; Bekaii-Saab, T.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
    Meeting Abstract

    Ku, G.; Bendell, J. C.; Tolcher, A. W.; Hurvitz, S. A.; Krishnamurthy, A.; El-Khoueiry, A. B.; Patnaik, A.; Shroff, R. T.; Noonan, A.; Hahn, N. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated mismatch repair proficient (MMRp) advanced tumours
    Meeting Abstract

    Rousseau, B. J. C.; Bieche, I.; Pasmant, E.; Simmet, V.; Hamzaoui, N.; Masliah-Planchon, J.; Pouessel, D.; Bruyas, A.; Augereau, P.; Grob, J. J.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab plus chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009
    Meeting Abstract

    Rugo, H. S.; Llombart Cussac, A.; AndreĢ, F.; Robson, M.; Saji, S.; Harbeck, N.; Schmid, P.; Cescon, D. W.; Seok Ahn, J.; Nanda, R.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save